Menu
Share this

PPD Appoints Veteran Bioanalytical Leader as Immunochemistry Head

Bruce Stouffer brings deep expertise to PPD® Laboratories

01 Jun. 2016

RSS

WILMINGTON, N.C., (June 1, 2016) – Pharmaceutical Product Development, LLC (PPD) today announced that Bruce Stouffer has joined PPD as executive director of immunochemistry in the PPD® Laboratories’ bioanalytical lab.

“Bruce brings extensive experience and strong leadership skills to our talented immunochemistry team,” said David Johnston, Ph.D., executive vice president of global laboratory services for PPD. “As a recognized industry leader, Bruce is an exceptional asset for our clients’ research programs.”

Stouffer previously served as director of analytical and bioanalytical development for Bristol-Myers Squibb, where he managed a group of scientists with responsibilities including contract operations, quality control, and small and large molecule bioanalytical project management. Previously, Stouffer was responsible for the bioanalytical sciences late-phase group, responsible for management of post-Phase II bioanalysis, as well as support for new chemical entity (NCE) filings.

Stouffer spent the early part of his research career in biomedical sciences as a technologist and lab supervisor at Roche Biomedical Labs. In 1982, he joined the Squibb Institute for Biomedical Research, developing immunoassays to support numerous small and large molecule programs for Bristol-Myers Squibb.

PPD Laboratories’ bioanalytical labs, located in Richmond, Virginia, and Middleton, Wisconsin, provide accurate and timely bioanalysis in a good laboratory practice (GLP)-compliant setting to advance small molecule and biologics development from preclinical studies through all phases of clinical trials. PPD’s immunochemistry scientists have contributed to the development of accepted industry methods for immunochemistry and are continually developing, validating and transferring new, industry-leading methods to the bioanalytical laboratory.

Stouffer received his bachelor’s degree in biology from Rider University.

About PPD
PPD is a leading global contract research organization providing comprehensive, integrated drug development, laboratory and lifecycle management services. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 46 countries and more than 15,000 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a firm commitment to quality to help clients and partners bend the cost and time curve of drug development to deliver life-changing therapies that improve health. For more information, visit www.ppdi.com.

PPD Contacts
Media:
Elizabeth Humphrey
+1 910 558 6096
elizabeth.humphrey@ppdi.com

Investors:
Nate Speicher
+1 910 558 6783
nate.speicher@ppdi.com

Except for historical information, all of the statements, expectations and assumptions, including statements, expectations and assumptions about the future performance of PPD Laboratories’ bioanalytical lab unit and employees contained in this news release are forward-looking statements that involve a number of risks and uncertainties. Although PPD attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based and could cause actual results to differ materially from the forward-looking statements. Other important factors that could cause future results to differ materially include the following: the ability to attract, integrate, retain and train key personnel; risks associated with and dependence on strategic relationships; risks associated with acquisitions and investments; competition in the outsourcing industry; PPD’s ability to win new business; overall global economic conditions; economic conditions, research and development spending, and outsourcing trends in the pharmaceutical, biotechnology and government-sponsored research sectors; loss, delay or modification of large contracts; higher-than-expected cancellation rates; the rate of conversion of backlog into revenue; consolidation in the pharmaceutical and biotechnology industries; rapid technological advances that make our services or capabilities less competitive; the ability to control SG&A spending; compliance with drug development regulations; changes in the regulation of the drug development process; and actual operating performance. PPD assumes no obligation and expressly disclaims any duty to update these forward-looking statements in the future, except as required by applicable law. These forward-looking statements should not be relied upon as representing PPD’s estimates or views as of any date subsequent to the date hereof.

Contact Us

Media Contacts:

Randy Buckwalter Senior Manager, Corporate Communications
PPD
Tel: +1 919 456 4425

Elizabeth Humphrey Corporate Communications Manager
PPD
Tel: +1 910 558 6096

Contact Legal Notices Modern Slavery Transparency Statement Privacy Policy

© 2017 Pharmaceutical Product Development, LLC. All rights reserved.